Biotechnology company specializing in developing psychoactive compounds aimed at treating mental health conditions and disorders PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) has filed a patent application with the United States Patent and Trademark Office (UPTSO) titled ‘Methods for Production of a Methylated Tryptamines and Intermediates or Side Products.’
In addition to methylated tryptamines, other psychedelics compounds like DMT and associated analogs were also included in the development of the potential treatment for mental health disorders.
This methylated tryptamines patent is aimed at potentially improving the treatments for mental health conditions including anxiety, addiction, post-traumatic stress disorder and depression.
“This innovative technology adds a wide range of new potential drug candidates to PsyBio’s portfolio of microbially derived small molecules. Leveraging the scalability and speed of a bacterial biosynthetic approach for these compounds is expected to lead to a cost completive synthesis with reduced environmental impact over current production methods,” said the chairman to company’s scientific advisory board, Dr. J. Andrew Jones.